IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Pursues Clinical Trials of Cannabis-Based Combination Therapies with Assistance of New Advisor

India Globalization Capital (NYSE MKT: IGC) recently named Craig Cheifetz, M.D. as an advisor to assist the company with its clinical trials in microbiology, immunology, neuroscience and biotechnology. IGC CEO Ram Mukunda stated in a news release that the company looks forward to Dr. Cheifetz’s contributions as IGC moves forward in the development of unique cannabis combination therapies. “The company anticipates clinical trials in 2017 for several indications, including pain, a huge market. IGC has already filed for six patents in areas such as eating disorders and epilepsy, in addition to pain. It is working on several more filings for indications including depression, Alzheimer’s and Parkinson’s disease. Its lead candidate is IGC-501, and it has filed patents for the candidate in the United States, Canada and Europe.”

To view the full article, visit http://nnw.fm/BzQ0Q

About India Globalization Capital, Inc.

India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland.